.png "TG Therapeutics (NASDAQ: TGTX)")
Today, a Director at TG Therapeutics (NASDAQ: TGTX), William James Kennedy, sold shares of TGTX for $337.2K.
Following William James Kennedy’s last TGTX Sell transaction on April 12, 2017, the stock climbed by 3.7%.
See today’s analyst top recommended stocks >>
Currently, TG Therapeutics has an average volume of 950.7K. The Company has a Price to Book ratio of 12.3918.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $31.50, reflecting a -56.2% downside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies.
Read More on TGTX:
